Genstar Capital completed the acquisition of a majority stake in Flourish Research.

Genstar Capital, a private equity firm, completed the acquisition of a majority stake in Flourish Research, a multi-site clinical trial organization focused on cardiovascular, metabolic, neuroscience, and infectious disease therapeutic areas. Financial terms were not disclosed. "Flourish owns and operates multiple clinical trial sites across the US that are leaders in scientific and medical expertise. With industry-leading data analytics, harmonized tools and systems, Flourish provides a unique opportunity to serve our clients with increased speed, quality, and meaningful patient diversity. With the support and investment from NMS Capital, we created a platform that is truly differentiated and equipped to scale to a global company, and our new partnership with Genstar will bolster this next phase of growth as we continue to advance the health and wellness of society through clinical trials," Reinhold Schulz, Flourish Research Chief Executive Officer.